Robin Smith, M.D., CEO of NeoStem, strikes up a conversation about stem cell research benefits with one of the largest, wealthiest organizations that are very publicly against embryonic stem cell research – the Roman Catholic Church.
Competition has picked up in the rare disease market which is now worth about $10 billion. Russell Basser, senior VP of global clinical research and development at CSL Behring reflects, “The rare disease space is becoming so crowded. We all have to be that much smarter about how we do business and it puts more pressure on drug development.”
There are various ways a young biotech company can improve their chances of success by having a well-defined commercialization strategy that is efficient and flexible, balancing commercialization progress with innovation and leveraging partnerships and collaboration with industry experts.
In 2013, many of the advancements in biotech didn’t come from biotech companies, they came from academia. Integrating academic institutions with the research and development pipeline with access to their facilities and research potential could are of major importance.
Today’s medicinal chemists and molecular and cell biologists often rely on sophisticated computer-based resources to assess a therapeutic area and to more efficiently interpret and analyze large volumes of information. To help control costs and move as quickly as possible through all aspects of development and clinical trials, biotechs have sought outside help.
GlaxoSmithKline’s head of science and innovation argues that the future progress of R&D industrywide depends on open but qualified sharing of all clinical-trials data.
The AIM IPO market has seen a number of significant listings recently in life sciences, especially for medical device and clinical services. For companies involved in drug discovery, the market remains challenging. But there are signs of interest in the drug discovery sector that the AIM market demonstrates a willingness to invest in businesses carrying out quality R&D, albeit in this case counter-balanced by a novel clinical services business.
Israel has been called, accurately, a nation of start-ups. With its scientifically oriented population and entrepreneurial drive, the nation is driving Middle East biotech. Approximately 60 percent of Israel’s life sciences companies focus on medical devices, while about 35 percent focus on biopharmaceuticals. Typically, 40 to 60 biotech companies are founded each year.
Sanofi will be the most productive and profitable R&D operation in the biopharmaceutical industry in 2015. That’s the vision of Elias Zerhouni, M.D., the company’s president of global R&D, and Sanofi CEO Chris Viehbacher, who persuaded Zerhouni, the former NIH director, to leave the world of academia where he had built a reputation as an innovative, successful, and charismatic leader.
What is the biggest mistake you have seen a c-level leader make?
|
|
|
|
|
|
|
|
|